Natera, Inc. presented compelling data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). This new assay offers an alternative for patients when tumor tissue is unavailable.
The clinical performance of the Latitude assay was analyzed in a cohort of approximately 200 patients, with over 1,300 plasma samples, from the GALAXY arm of the CIRCULATE-Japan study. The assay demonstrated a clinical sensitivity to recurrence of 58% in the post-surgical MRD window and 81% in the surveillance setting, with a median diagnostic lead time of 4.6 months.
The Latitude assay also exhibited high clinical specificity, with patient-level specificity at 92% and sample-level specificity at 97% in the surveillance setting. Furthermore, MRD positivity was highly prognostic of recurrence risk, showing a hazard ratio of 10 (p<0.0001), and high-risk stage II and stage III MRD-positive patients derived significant benefit from adjuvant chemotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.